JP2020519672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519672A5 JP2020519672A5 JP2019563217A JP2019563217A JP2020519672A5 JP 2020519672 A5 JP2020519672 A5 JP 2020519672A5 JP 2019563217 A JP2019563217 A JP 2019563217A JP 2019563217 A JP2019563217 A JP 2019563217A JP 2020519672 A5 JP2020519672 A5 JP 2020519672A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- ret
- combination according
- mtorc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GBLBJPZSROAGMF-RWYJCYHVSA-N C[C@@H](c(cc1)cnc1-[n]1ncc(F)c1)NC([C@](CC1)(CC[C@@H]1c1nc(Nc2n[nH]c(C)c2)cc(C)n1)OC)=O Chemical compound C[C@@H](c(cc1)cnc1-[n]1ncc(F)c1)NC([C@](CC1)(CC[C@@H]1c1nc(Nc2n[nH]c(C)c2)cc(C)n1)OC)=O GBLBJPZSROAGMF-RWYJCYHVSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506334P | 2017-05-15 | 2017-05-15 | |
| US62/506,334 | 2017-05-15 | ||
| US201862652284P | 2018-04-03 | 2018-04-03 | |
| US62/652,284 | 2018-04-03 | ||
| US201862656297P | 2018-04-11 | 2018-04-11 | |
| US62/656,297 | 2018-04-11 | ||
| US201862657605P | 2018-04-13 | 2018-04-13 | |
| US62/657,605 | 2018-04-13 | ||
| PCT/US2018/032794 WO2018213329A1 (en) | 2017-05-15 | 2018-05-15 | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519672A JP2020519672A (ja) | 2020-07-02 |
| JP2020519672A5 true JP2020519672A5 (https=) | 2021-07-26 |
Family
ID=62567777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563217A Withdrawn JP2020519672A (ja) | 2017-05-15 | 2018-05-15 | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210290620A1 (https=) |
| EP (1) | EP3624802A1 (https=) |
| JP (1) | JP2020519672A (https=) |
| CN (1) | CN110891573A (https=) |
| WO (1) | WO2018213329A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| PE20210096A1 (es) * | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| EP4157230A1 (en) * | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Pralsetinib pharmaceutical compositions |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128042A2 (en) | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Methods of identifying mutations in nucleic acid |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| CN103764676A (zh) | 2011-08-04 | 2014-04-30 | 日本国立癌症研究中心 | Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法 |
| BR112014004213A2 (pt) | 2011-08-23 | 2017-06-20 | Found Medicine Inc | novas moléculas de fusão kif5b-ret e usos das mesmas |
| US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| AU2013259267A1 (en) * | 2012-05-10 | 2014-11-06 | Synta Pharmaceuticals Corp. | Treating cancer with Hsp90 inhibitory compounds |
| EP2878672A4 (en) | 2012-07-26 | 2016-02-17 | Nat Cancer Ct | FUSIONSGEN OF CEP55-GEN AND RET-GEN |
| MY170904A (en) | 2012-09-25 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| SMT201700152T1 (it) | 2013-03-15 | 2017-05-08 | Glaxosmithkline Ip Dev Ltd | Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret) |
| WO2015006875A1 (en) | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
| CN105658814A (zh) | 2013-08-20 | 2016-06-08 | 日本国立癌症研究中心 | 在肺癌中检测出的新型融合基因 |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| WO2016038552A1 (en) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
| WO2016037578A1 (en) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
| KR102562866B1 (ko) | 2014-11-14 | 2023-08-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
-
2018
- 2018-05-15 JP JP2019563217A patent/JP2020519672A/ja not_active Withdrawn
- 2018-05-15 WO PCT/US2018/032794 patent/WO2018213329A1/en not_active Ceased
- 2018-05-15 CN CN201880046867.7A patent/CN110891573A/zh active Pending
- 2018-05-15 US US16/613,625 patent/US20210290620A1/en not_active Abandoned
- 2018-05-15 EP EP18730519.8A patent/EP3624802A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519672A5 (https=) | ||
| JP2021520349A5 (https=) | ||
| US20230226092A1 (en) | Cancer treatments based on gemcitabine prodrugs | |
| Walenkamp et al. | Clinical and therapeutic aspects of extrapulmonary small cell carcinoma | |
| US20230218655A1 (en) | Cancer treatments | |
| JP2020514292A5 (https=) | ||
| JP2020527139A5 (https=) | ||
| JP2008546640A5 (https=) | ||
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| Butt et al. | BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series | |
| Gray et al. | Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab | |
| Roldán et al. | A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab | |
| Chang et al. | A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement | |
| Gao et al. | Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients | |
| Melichar et al. | Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy | |
| Vassos et al. | A novel complex KIT mutation in a gastrointestinal stromal tumor of the vermiform appendix | |
| TW201803566A (zh) | 用於癌症治療之維持療法 | |
| Alzarkali et al. | Ipilimumab and Nivolumab After Disease Progression on Single Agent Immunotherapy in Mismatch Repair Deficient Metastatic Colorectal Cancer | |
| RU2020135917A (ru) | Ингибитор ret для применения в лечении рака, имеющего ret-альтерацию | |
| Rivera et al. | Adjuvant radiotherapy for rectal cancer: recent results, new questions | |
| Ohashi et al. | Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer | |
| Fiorentino et al. | Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations | |
| Lee et al. | MET-amplified intramucosal gastric cancer widely metastatic after complete endoscopic submucosal dissection | |
| RU2021131604A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих инсерции в экзоне 21 her2 | |
| Green | Investigating the role played by inflammation in the development of BRAFV600E-driven colorectal cancer |